博瑞醫藥(688166.SH):與關聯方設合資公司 以吸入製劑用原料藥為核心業務
格隆匯 8 月 17日丨博瑞醫藥(688166.SH)公佈,公司與關聯方博諾康源(北京)藥業科技有限公司(“博諾康源”)簽署投資協議,共同投資設立博澤格霖(山東)藥業有限公司(“合資公司”),註冊資本為2000萬元人民幣,其中博瑞醫藥以自有資金出資980萬元,佔合資公司註冊資本的比例為49%。
合資公司以吸入製劑用原料藥的研發、生產和銷售為核心業務。此次對外投資有利於博瑞醫藥在吸入製劑用原料藥領域的戰略佈局。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.